Welcome to our dedicated page for Novanta SEC filings (Ticker: NOVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novanta Inc. filings document the company's operating results, governance matters and capital structure as an operating technology supplier to medical and advanced technology equipment manufacturers. Form 8-K reports furnish earnings releases and financial guidance updates, report board and committee changes, and disclose authorizations for common-share repurchases.
The company's filings also include capital-markets disclosures for Novanta's 6.50% tangible equity units, including underwriting arrangements, unit issuance and related registration-statement references. The definitive proxy statement covers shareholder voting matters, board governance, executive compensation, equity awards and pay-versus-performance information for the company's annual meeting process.
Novanta Inc. reported solid first quarter 2026 results with growth in sales, earnings on a non-GAAP basis, and strong cash generation. GAAP revenue rose 10.4% to $257.7 million, helped by acquisitions and favorable currency, while organic revenue increased 3.1%. GAAP net income was stable at $21.1 million, but diluted EPS declined to $0.51 from $0.59 as operating expenses grew.
Profitability looked stronger on a non-GAAP basis. Adjusted EBITDA increased 14.2% to $57.1 million, with margin at 22.1%, and Adjusted diluted EPS rose to $0.81 from $0.74. Operating cash flow jumped to $51.6 million, driving Free Cash Flow of $47.8 million and leaving the company in a net cash position of about $139 million. Management highlighted 37% year-over-year bookings growth and guided Q2 2026 GAAP revenue to $259–$264 million, with full-year 2026 revenue expected between $1.04 billion and $1.055 billion, and higher Adjusted EBITDA and EPS, reflecting confidence in demand across medical and advanced industrial end markets.
Novanta Inc. Chief Executive Officer Matthijs Glastra sold 6,500 shares of common stock in open-market transactions on May 5, 2026, under a pre-established Rule 10b5-1 trading plan. The trades were executed at weighted-average prices within disclosed ranges, and Glastra also reports indirect ownership of 54,382 shares through a 2021 irrevocable trust.
Novanta, Inc. (NOVT) related party filed a Form 144 to sell common stock. The filing lists 6,500 shares with an aggregate value of $845,000 and references 35,683,769 shares outstanding as of 05/05/2026. The notice names Merrill Private Wealth Management and shows multiple recent sales by Matthijs Glastra totaling repeated tranches of 6,500 and 7,500 shares on dates in early 2026.
Novanta Inc reports a Schedule 13G filing showing Vanguard Capital Management beneficially owns 1,886,765 shares (5.27%). The filing states Vanguard has sole dispositive power over 1,886,765 shares and sole voting power over 273,550 shares. The filing is signed by Ashley Grim on 04/30/2026.
This Schedule 13G discloses ownership on behalf of Vanguard-managed accounts, noting holdings include securities held by Vanguard funds and certain affiliates. The filing lists corporate addresses for Novanta and Vanguard and affirms no single other person holds more than 5% of the class.
Vanguard Portfolio Management reported beneficial ownership of 2,508,270 shares of Novanta Inc Common Stock, representing 7.01% of the class as of 03/31/2026. The filing shows sole voting power for 31,389 shares and sole dispositive power for 2,508,270 shares. The disclosure was signed on 04/29/2026 by Ashley Grim.
Novanta Inc. is calling a virtual 2026 annual shareholder meeting on May 28 to elect nine directors, hold an advisory vote on executive pay, and ratify Deloitte & Touche LLP as auditor until the 2027 meeting. Shareholders of record on April 14, 2026 can vote online, by phone, or by mail.
The board has nine members, eight of whom are independent, with a combined Chair/CEO and a separate independent Lead Director. Directors receive cash retainers and annual restricted stock units, and an annual “say‑on‑pay” vote will continue. Deloitte, auditor since 2024, received total fees of $2.32 million in 2025, mainly for audit work.
Novanta Inc. Chief Executive Officer Matthijs Glastra reported an open-market sale of 6,500 shares of common stock. The shares were sold at a weighted-average price of $130.05 per share on April 17, 2026, under a pre-established Rule 10b5-1 trading plan.
Following this sale, he directly owns 56,761 shares of Novanta common stock and has an additional 54,382 shares held indirectly through the Matthijs Glastra 2021 Irrevocable Trust. The transaction was executed in multiple trades between $130.00 and $130.28 per share.
Novanta, Inc. filing under Rule 144 discloses recent restricted stock unit grants and several secondary sales by a reporting holder. The excerpt lists RSU grants dated 02/24/2025 (1,900 shares), 02/28/2020 (2,076 shares) and earlier grants, and four sales by Matthijs Glastra on 01/21/2026, 02/02/2026, 02/10/2026, and 03/02/2026 for 7,500; 6,500; 7,500; and 6,500 shares respectively, with corresponding gross amounts shown.
Novanta Inc: The Vanguard Group filed an amended Schedule 13G/A reporting zero shares beneficially owned and 0% of Novanta Inc common stock following an internal realignment. The filing explains certain Vanguard subsidiaries will report disaggregated holdings after the January 12, 2026 realignment. The form is signed by Ashley Grim on 03/27/2026.